Antipsychotic Treatment Duration in Children and Adolescents: A Register-Based Nationwide Study.

Despite the increasing use of antipsychotic drugs in children and adolescents in many countries, little is known about the treatment duration in this vulnerable population. The present nationwide study investigated the duration of antipsychotic treatment and factors associated with treatment discontinuation in Finnish children and adolescents. All subjects aged 1-17 years who had started a second-generation antipsychotic (SGA) drug (risperidone, quetiapine, aripiprazole, or olanzapine) between January 2008 and December 2016 ( = 20,932) were extracted from the Finnish Prescription Registry and followed up until December 31, 2017.

New Users of Antipsychotics Among Children and Adolescents in 2008-2017: A Nationwide Register Study.

Introduction: Recently, prescribing antipsychotics for children and adolescents has been increasing in many countries. These drugs are often prescribed off-label, although antipsychotics have been associated with adverse effects. We determined the recent incidence of antipsychotic use among children and adolescents in Finland.

Short-term cognitive improvement in schizophrenics treated with typical and atypical neuroleptics.

Objective: Atypical neuroleptics seem to be more beneficial than typical ones with respect to long-term neuropsychological functioning. Thus, most studies focus on the long-term effects of neuroleptics. We were interested in whether atypical neuroleptic treatment is also superior to typical drugs over relatively short periods of time.